NCT05147740View on ClinicalTrials.gov

Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

PHASE4UnknownINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

HIV-1-infection

Interventions

DRUG

B/F/TAF

50/200/25 mg fixed-dose combination administered orally once daily without regard to food.

Trial Locations (1)

92262

RECRUITING

DAP Health, Palm Springs

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Tulika Singh, MD

OTHER